Please assess the completion status of the following clinical trial:

Trial Title: A Study of the Efficacy and Safety of ICA-17043 (With or Without Hydroxyurea) in Patients With Sickle Cell Anemia.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Homozygous (HbSS) Sickle Cell Anemia~* Otherwise healthy (based on medical history, physical examination, 12-lead ECG, and clinical laboratory tests)~* Patients may be receiving hydroxyurea, but must have been dose stabilized for at least 3 months~* Patient has a history of at least one acute vaso-occlusive event requiring hospitalization~Exclusion Criteria:~* Patient participating in a chronic transfusion program~* Patient having a total hemoglobin of \< 4.0 g/dL or \> 10.0 g/dL~* Patient having a HbA \> 10%~* Patient considering undergoing an elective surgery~* Patient taking prohibited medications such as Epoetin, Warfarin, etc.~* Patient who has had previous gastrointestinal surgery, except cholecystectomy or appendectomy~* Patient with significant active cardiovascular, neurologic, endocrine, hepatic, or renal disorders unrelated to sickle cell anemia

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- ICA-17043 Low Dose 6 mg/day (Type: EXPERIMENTAL): Active study medication: 100 mg loading dose; 6 mg maintenance dose per day
- Placebo (Type: PLACEBO_COMPARATOR): None
- ICA-17043 High Dose 10 mg/day (Type: EXPERIMENTAL): Active study medication: 150 mg loading dose; 10 mg maintenance dose per day

Based on this trial design, predict the completion outcome and termination type (if applicable).